ADPT Adaptive Biotechnologies Corp
Company Analysis
Latest News
🔴 Adaptive Biotechnologies is trading 4.3% down
Adaptive Biotechnologies is trading 4.3% lower at $24.49, with no clear company-specific announcement explaining the October 16, 2026 decline. - A reported...
🔴 Adaptive Biotechnologies is trading 5.1% down in pre-market with no clear company-specific catalyst
Adaptive Biotechnologies is trading at $24.32, down 5.07%, with no identified company-specific announcement explaining the October 15 pre-market decline. -...
🔴 Adaptive Biotechnologies is trading 7.04% down in pre-market
Adaptive Biotechnologies is trading 7.04% lower at $23.50 in pre-market, with no clear company-specific announcement or broader-market move identified to...
🔴 Adaptive Biotechnologies is trading 4.02% down with no clear company-specific catalyst
Adaptive Biotechnologies is trading 4.02% down now at $25.43, with no clear company-specific announcement or catalyst identified for the October 12, 2026...
🔴 Adaptive Biotechnologies is trading 4.13% down today as higher Treasury yields weigh on biotech stocks
Adaptive Biotechnologies is trading at $25.20, down 4.13%, with no fresh company-specific catalyst identified amid broader market weakness. - The decline...
🔴 Adaptive Biotechnologies is trading 4.39% down amid biotech-sector weakness
Adaptive Biotechnologies is trading 4.39% down at $28.53; biotech-sector weakness may be contributing, but no clear company-specific announcement explaining...
🟢 Adaptive Biotechnologies is trading 4.09% up today amid broader-market strength led by growth stocks
Adaptive Biotechnologies is trading at $29.51, up 4.09%, amid broader-market gains; no company-specific catalyst was identified for the move. - On October 5,...
🔴 Adaptive Biotechnologies is trading 4.3% down with no clear company-specific catalyst identified
Adaptive Biotechnologies is trading 4.3% lower at $27.66 on October 1; no clear company-specific catalyst has been identified. - The sharp intraday decline...
Adaptive Biotechnologies Gains Goldman Sachs Buy Rating, $35 Target
Goldman Sachs initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and a $35.00 price target. The firm cited the company’s growth potential...
🔴 Adaptive Biotechnologies is trading 4.52% down amid broad market weakness
Adaptive Biotechnologies is trading 4.52% lower at $28.10 on September 28, with no clear company-specific catalyst identified as broader markets decline. -...
🔴 Adaptive Biotechnologies is trading 5.71% down in after-hours trading with no clear catalyst identified
Adaptive Biotechnologies is trading 5.71% lower at $27.75 in after-hours trading; no clear catalyst for the decline was identified. - Shares closed at $29.43...
🟢 Adaptive Biotechnologies is trading 4.3% up today after BTIG raised its price target to $34
Adaptive Biotechnologies is trading 4.3% up at $29.07 after BTIG raised its price target to $34 from $25 and maintained a Buy rating on September 22. - BTIG...
🔴 Adaptive Biotechnologies is trading 5% down in pre-market with no clear company-specific catalyst
Adaptive Biotechnologies is trading 4.85% down at $26.51 in pre-market on September 22, 2026, after closing at $27.86 on September 21; no fresh...
🟢 Adaptive Biotechnologies is trading 4.7% up in pre-market amid broad risk-on sentiment
Adaptive Biotechnologies is trading 4.7% higher at $29.97, primarily in line with broader risk-on sentiment rather than a fresh company-specific catalyst. -...
🟢 Adaptive Biotechnologies is trading 4.7% up today on MRD and Immune Medicine separation progress
Adaptive Biotechnologies is trading 4.7% up now at $28.06, as investors respond to management’s Morgan Stanley fireside chat highlighting progress separating...
Adaptive Biotech Surges 10% Before a Fireside Chat — But Can a Conference Appearance Justify a $400 Million Leap in Market Value?
Shares of Adaptive Biotechnologies jolted 10.3% higher to $27.33 on a day when the broader biotech sector traded weaker, as investors positioned ahead of the...
🟢 Adaptive Biotechnologies Surges 10.29% as Investors Cheer Progress on Unit Separation at Morgan Stanley Fireside Chat
Adaptive Biotechnologies is trading at $27.33 (+10.29%) today. - The surge is driven by investor enthusiasm following management's updates at the Morgan...
🟢 Adaptive Biotechnologies is trading 4.68% up today possibly linked to Morgan Stanley conference appearance
Adaptive Biotechnologies is trading 4.68% up now at $25.94, with investor interest possibly supported by its upcoming Morgan Stanley healthcare conference...
🔴 Adaptive Biotechnologies is trading 5% down in pre-market
Adaptive Biotechnologies is trading 5.28% down at $22.95, after falling from the September 10 close of $24.23, with no clear catalyst identified for September...
🟢 Adaptive Biotechnologies is trading 6.4% up in pre-market with no clear catalyst identified
Adaptive Biotechnologies is trading at $25.99, up 6.4%, with no clear catalyst identified. - The stock rose from its September 9 close of $24.42; no fresh...